Gallium Ga-68 PSMA-11

GALLIUM GA-68 PSMA-11- gallium ga-68 gozetotide injection, solution
UCSF Radiopharmaceutical Facility


Ga 68 PSMA-11 Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.


2.1 Radiation Safety – Drug Handling

Handle Ga 68 PSMA-11 Injection with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions (5.2)]. Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Ga 68 PSMA-11 Injection.

Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.

2.2 Recommended Dosage and Administration Instructions

Recommended Dosage

In adults, the recommended amount of radioactivity to be administered for PET is 111 MBq to 259 MBq (3 mCi to 7 mCi) administered as an intravenous bolus injection.


  • Use aseptic technique and radiation shielding when withdrawing and administering Ga 68 PSMA-11 Injection.
  • Calculate the necessary volume to administer based on calibration time and required dose.
  • Inspect Ga 68 PSMA-11 Injection visually for particulate matter and discoloration before administration. Do not use the drug if the solution contains particulate matter or is discolored.
  • Ga 68 PSMA-11 Injection may be diluted with sterile 0.9% Sodium Chloride Injection, USP.
  • Assay the final dose immediately before administration to the patient in a dose calibrator.
  • After injection of Ga 68 PSMA-11 Injection, administer an intravenous flush of sterile 0.9% Sodium Chloride Injection, USP to ensure full delivery of the dose.
  • Dispose of any unused drug in a safe manner in compliance with applicable regulations.
  • Unless contraindicated, a diuretic expected to act within the uptake time period may be administered at the time of radiotracer injection to potentially decrease artifact from radiotracer accumulation in the urinary bladder and ureters.

2.3 Patient Preparation Prior to PET Imaging

Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to administration of Ga 68 PSMA-11 Injection and to continue to drink and void frequently following administration to reduce radiation exposure, particularly during the first hour after administration [see Warnings and Precautions (5.2)].

2.4 Image Acquisition

Position the patient supine with arms above the head. Begin PET scanning 50 to 100 minutes after the intravenous administration of Ga 68 PSMA-11 Injection. Patients should void immediately prior to image acquisition and that image acquisition should begin at the proximal thighs and proceed cranially to the skull base or skull vertex. Adapt imaging technique according to the equipment used and patient characteristics in order to obtain the best image quality possible.

2.5 Image Interpretation

Ga 68 PSMA-11 binds to prostate-specific membrane antigen (PSMA). Based on the intensity of the signals, PET images obtained using Ga 68 PSMA-11 Injection indicate the presence of PSMA in tissues. Lesions should be considered suspicious if uptake is greater than physiologic uptake in that tissue or greater than adjacent background if no physiologic uptake is expected. Tumors that do not bear PSMA will not be visualized. Increased uptake in tumors is not specific for prostate cancer [see Warnings and Precautions (5.1)].

2.6 Radiation Dosimetry

Estimated radiation absorbed doses per injected activity for organs and tissues of adult male patients following an intravenous bolus of Ga 68 PSMA-11 Injection are shown in Table 1.

The effective radiation dose resulting from the administration of 259 MBq (7 mCi) is about 4.4 mSv. The radiation doses for this administered dose to the critical organs, which are the kidneys, urinary bladder, and spleen, are 96.2 mGy, 25.4 mGy, and 16.8 mGy, respectively.

These radiation doses are for Ga 68 PSMA-11 Injection alone. If CT or a transmission source are used for attenuation correction, the radiation dose will increase by an amount that varies by technique.

Table 1: Estimated Radiation Absorbed Dose per Injected Activity in Selected Organs and Tissues of Adults after Intravenous Administration of Ga 68 PSMA-11 Injection
Organ Absorbed dose (mGy/MBq)
Mean SD
Adrenals 0.0156 0.0014
Brain 0.0104 0.0011
Breasts 0.0103 0.0011
Gallbladder 0.0157 0.0012
Lower Colon 0.0134 0.0009
Small Intestine 0.0140 0.0020
Stomach 0.0129 0.0008
Heart 0.0120 0.0009
Kidneys 0.3714 0.0922
Liver 0.0409 0.0076
Lungs 0.0111 0.0007
Muscle 0.0103 0.0003
Pancreas 0.0147 0.0009
Red Marrow 0.0114 0.0016
Skin 0.0091 0.0003
Spleen 0.0650 0.0180
Testes 0.0111 0.0006
Thymus 0.0105 0.0006
Thyroid 0.0104 0.0006
Urinary Bladder 0.0982 0.0286
Total Body 0.0143 0.0013
Effective Dose (mSv/MBq) 0.0169 0.0015
Page 1 of 4 1 2 3 4

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.